Study details
Enrolling now
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136)
Eli Lilly and Company
NCT IDNCT07215559ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
200
Study length
about 1.6 years
Ages
18–75
Locations
22 sites in AZ, GA, NJ +5
About this study
Researchers are testing macupatide and eloralintide, alone or in combination, to see if they help people with obesity or overweight who also have type 2 diabetes lose weight. The trial will last about 48 weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Eloralintide
- 2.Take Eloralintide Placebo
- 3.Take Macupatide
- +1 more
PhasePhase 2
Primary goalPercent Change from Baseline in Body Weight
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Percent Change from Baseline in Body Weight
Secondary: Change from Baseline in Body Mass Index (BMI), Change from Baseline in Fasting Glucose, Change from Baseline in Hemoglobin A1c (HbA1c)
Body systems
Endocrinology